share_log

Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update

Financial News Live ·  Nov 17, 2022 13:01

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 16,600 shares, a growth of 9.2% from the October 15th total of 15,200 shares. Based on an average daily trading volume, of 12,200 shares, the short-interest ratio is presently 1.4 days. Currently, 0.3% of the company's shares are sold short.

Indaptus Therapeutics Price Performance

Shares of INDP traded down $0.07 during trading hours on Wednesday, reaching $1.66. The stock had a trading volume of 9,671 shares, compared to its average volume of 183,180. Indaptus Therapeutics has a 12 month low of $1.64 and a 12 month high of $7.10. The firm has a 50-day simple moving average of $2.13 and a 200 day simple moving average of $2.48.

Get Indaptus Therapeutics alerts:

Insiders Place Their Bets

In other Indaptus Therapeutics news, CEO Jeffrey A. Meckler purchased 10,308 shares of the business's stock in a transaction on Thursday, September 8th. The shares were purchased at an average cost of $2.80 per share, for a total transaction of $28,862.40. Following the acquisition, the chief executive officer now owns 65,374 shares of the company's stock, valued at $183,047.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 36.00% of the company's stock.

Hedge Funds Weigh In On Indaptus Therapeutics

A number of large investors have recently modified their holdings of INDP. Vanguard Group Inc. lifted its holdings in shares of Indaptus Therapeutics by 18.7% in the 1st quarter. Vanguard Group Inc. now owns 242,235 shares of the company's stock worth $969,000 after purchasing an additional 38,216 shares in the last quarter. Northern Trust Corp bought a new position in shares of Indaptus Therapeutics in the 1st quarter worth $41,000. State Street Corp bought a new position in shares of Indaptus Therapeutics in the 1st quarter worth $78,000. Renaissance Technologies LLC bought a new position in shares of Indaptus Therapeutics in the 2nd quarter worth $51,000. Finally, Strategy Asset Managers LLC bought a new position in Indaptus Therapeutics during the 3rd quarter valued at $120,000. 19.25% of the stock is currently owned by institutional investors.

Indaptus Therapeutics Company Profile

(Get Rating)

Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial.

Featured Articles

  • Get a free copy of the StockNews.com research report on Indaptus Therapeutics (INDP)
  • Why Lowe's Is Up And Home Depot Down
  • The TJX Companies Could Break Out To New Highs
  • Gold Rush: Newmont Corp. is Starting to Sparkle
  • Four Healthcare Stocks To Watch This Week
  • Will It Be Smooth Sailing For Carnival After 56% One-Month Rally?

Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment